Teriparatide - Osteoporosis
You are here : Home > Formulary Search > Teriparatide - Osteoporosis
Status 1
- Injection
Documentation
PAD Profile
Post-menopausal osteoporosis in women. Rheumatology only.
See separate entry for use in men and juveniles.
Biosimilar teriparatide is recommended. Prescribe by brand.
Other Indications
Below are listed other indications that Teriparatide is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Osteoporosis.
Committee Recommendations (2)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the use of teriparatide for osteoporosis in postmenopausal women in line with its licence (24 months treatment length).
Teriparatide will continue to have RED traffic light status for use in this patient cohort.
The updated definitions for use and severity in the national guidance for osteoporosis treatment from the NOGG/ROC (2024 recommendations) was agreed to enable access to teriparatide, romosozumab and abaloparatide at patients at high risk. National Osteoporosis Guidelines Group UK
The APC recommends the use of biosimilar teriparatide in all new patients for all CCG-commissioned indications.
Teriparatide is considered as RED on the traffic light system.
Prescribing would be by hospital specialists only, in line with NICE and using the Blueteq initiation and repeat treatment forms.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Please note: the Medicines Healthcare Products Regulatory Agency (MHRA) recommends that biological products are prescribed by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist.